Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Published:2021-02 Issue:2 Volume:21 Page:226-240
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bassetti Matteo,Echols Roger,Matsunaga Yuko,Ariyasu Mari,Doi Yohei,Ferrer Ricard,Lodise Thomas P,Naas Thierry,Niki Yoshihito,Paterson David L,Portsmouth Simon,Torre-Cisneros Julian,Toyoizumi Kiichiro,Wunderink Richard G,Nagata Tsutae D

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference32 articles.

1. White paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs;Boucher;J Infect Dis,2017

2. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics,2017

3. European prospective cohort study on enterobacteriaceae showing resistance to carbapenems (EURECA): a protocol of a European multicentre observational study;Gutiérrez-Gutiérrez;BMJ Open,2017

4. Treatment options for carbapenem-resistant Gram-negative bacterial infections;Doi;Clin Infect Dis,2019

5. New treatment options for multiresistant Gram negatives;Paterson;Curr Opin Infect Dis,2020

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic within-host cefiderocol heteroresistance caused by blaSHV-12 amplification in pandrug-resistant and hypervirulent Klebsiella pneumoniae sequence type 11;Drug Resistance Updates;2024-03

2. How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework;The Lancet Infectious Diseases;2024-02

3. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.;Journal of Infection;2024-02

4. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis;International Journal of Antimicrobial Agents;2024-02

5. New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties;Transplant International;2024-02-01